Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17875571 | 0.91 | PARP1 (0.44) | PARP1DAOSLC6A2SLC6A4KCNH2 | |
| SCHEMBL1835087 | 0.88 | PARP1 (0.40) | PARP1HTR1A | |
| SCHEMBL16362041 | 0.87 | DRD1 (0.49) | PARP1DAOSLC6A2SLC6A4KCNH2 | |
| SCHEMBL1840364 | 0.87 | DRD1 (0.45) | PARP1DAOSLC6A2SLC6A4KCNH2 | |
| SCHEMBL16362124 | 0.87 | PARP1 (0.41) | PARP1DAOSLC6A2SLC6A4KCNH2 | |
| SCHEMBL16362125 | 0.87 | PARP1 (0.41) | PARP1DAOSLC6A2SLC6A4KCNH2 | |
| SCHEMBL1835217 | 0.86 | PARP1 (0.39) | PARP1HTR1A | |
| SCHEMBL16362122 | 0.85 | PARP1 (0.40) | PARP1HCRTR1HCRTR2 | |
| SCHEMBL17876322 | 0.85 | PARP1 (0.40) | PARP1SLC6A2SLC6A4KCNH2HRH1 | |
| SCHEMBL17876422 | 0.84 | PARP1 (0.47) | PARP1DAOSLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579641-B2 | Aryl phosphines with fused ring ortho-alkoxy substitution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579641-B2 | Aryl phosphines with fused ring ortho-alkoxy substitution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579641-B2 | Aryl phosphines with fused ring ortho-alkoxy substitution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2321244-B1 | IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3010927-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | Dow Global Technologies LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014205025-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014205025-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-12-24 | — | — | WO | disclosed |
| US-8558030-B2 | Process for telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2321244-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019360-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | HRH3, HRH4, TELO2 | PARP1 389/4885DAO 2254/4885SLC6A2 4580/4885 |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | ALK, PHOSPHO1, MPL | PARP1 3058/4885DAO 875/4885SLC6A2 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.